CA3201936A1 - Crystal form of tolebrutinib and preparation method thereof - Google Patents

Crystal form of tolebrutinib and preparation method thereof

Info

Publication number
CA3201936A1
CA3201936A1 CA3201936A CA3201936A CA3201936A1 CA 3201936 A1 CA3201936 A1 CA 3201936A1 CA 3201936 A CA3201936 A CA 3201936A CA 3201936 A CA3201936 A CA 3201936A CA 3201936 A1 CA3201936 A1 CA 3201936A1
Authority
CA
Canada
Prior art keywords
compound
amorphous
present disclosure
crystalline form
csi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201936A
Other languages
English (en)
French (fr)
Inventor
Minhua Chen
Jiaming Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA3201936A1 publication Critical patent/CA3201936A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3201936A 2020-12-10 2021-11-22 Crystal form of tolebrutinib and preparation method thereof Pending CA3201936A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011455573.5 2020-12-10
CN202011455573 2020-12-10
PCT/CN2021/132028 WO2022121670A1 (zh) 2020-12-10 2021-11-22 Tolebrutinib的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
CA3201936A1 true CA3201936A1 (en) 2022-06-16

Family

ID=81974189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201936A Pending CA3201936A1 (en) 2020-12-10 2021-11-22 Crystal form of tolebrutinib and preparation method thereof

Country Status (11)

Country Link
US (2) US12049463B2 (https=)
EP (1) EP4261212A4 (https=)
JP (2) JP2023553930A (https=)
KR (1) KR102872880B1 (https=)
CN (1) CN118434732A (https=)
AU (1) AU2021398051A1 (https=)
CA (1) CA3201936A1 (https=)
CO (1) CO2023008949A2 (https=)
IL (1) IL303590A (https=)
MX (1) MX2023006854A (https=)
WO (1) WO2022121670A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022014058A2 (pt) 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A4 (en) 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
US20250145618A1 (en) * 2021-12-21 2025-05-08 Principia Biopharma Inc. Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof
WO2023172663A1 (en) 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CN101056877B (zh) 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
TW200911803A (en) 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
CN103502249A (zh) 2011-05-17 2014-01-08 普林斯匹亚生物制药公司 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CN102942567B (zh) * 2012-11-09 2017-02-08 诸城市浩天药业有限公司 吡咯并喹啉醌的二钠盐结晶
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2015132799A2 (en) 2014-02-03 2015-09-11 Cadila Healthcare Limited Novel heterocyclic compounds
ES2860648T5 (es) * 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
JP2016094368A (ja) * 2014-11-14 2016-05-26 大日本住友製薬株式会社 ベンズイミダゾール化合物の新規結晶、及びその製造方法
WO2016086358A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
SI3377484T1 (sl) 2015-11-17 2024-02-29 Merck Patent Gmbh Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
BR112022014058A2 (pt) * 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
US12448363B2 (en) 2020-06-02 2025-10-21 Vidya Therapeutics, Inc. Kinase inhibitors
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
US20240051955A1 (en) 2020-12-23 2024-02-15 Genzyme Corporation 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
EP4328226A4 (en) 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF
CN117412749A (zh) 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2022257845A1 (zh) 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
US20250145618A1 (en) 2021-12-21 2025-05-08 Principia Biopharma Inc. Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof
US20260027100A1 (en) 2022-05-13 2026-01-29 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad)
CA3259743A1 (en) 2022-06-22 2023-12-28 Principia Biopharma Inc. METHODS FOR MANUFACTURING MODIFIED BTK INHIBITORS
CA3260159A1 (en) 2022-06-30 2024-01-04 Principia Biopharma Inc. Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis

Also Published As

Publication number Publication date
WO2022121670A1 (zh) 2022-06-16
CN118434732A (zh) 2024-08-02
US12049463B2 (en) 2024-07-30
AU2021398051A1 (en) 2023-07-27
US20220389011A1 (en) 2022-12-08
KR102872880B1 (ko) 2025-10-20
EP4261212A4 (en) 2024-11-27
JP2023553930A (ja) 2023-12-26
KR20230118154A (ko) 2023-08-10
AU2021398051A9 (en) 2024-10-17
JP2026041905A (ja) 2026-03-10
CO2023008949A2 (es) 2023-09-29
IL303590A (en) 2023-08-01
MX2023006854A (es) 2023-07-20
EP4261212A1 (en) 2023-10-18
US20240391915A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
US12049463B2 (en) Crystalline form of Tolebrutinib
EP3682884B1 (en) Crystalline forms of daprodustat (gsk1278863), a peroral hypoxia-inducible factor prolyl hydroxylase inhibitor (hif-phi) for treating anemia, and their preparation methods
EP4353723A1 (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
US11572365B2 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
AU2015237744A1 (en) Ibrutinib solid forms and production process therefor
US10752595B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN110312705B (zh) Gft-505的晶型及其制备方法和用途
HK40094757A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
HK40111001A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4509499A1 (en) Polymorph of 7,8-dihydroxyflavone, and preparation method therefor
AU2023218670A1 (en) Crystal form of cyclohexenone compound
KR20250144411A (ko) 벤조 질소 헤테로 방향족 고리 유도체의 염, 결정형 및 이의 의약적 응용
CA3170562A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
CN119403807A (zh) 5H－吡咯并［2,3－d］嘧啶－6（7H）－酮及其盐体的结晶
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241106

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241106

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241106

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250611

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250611

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250627

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251121

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH

Effective date: 20251121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251121

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251201

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251201

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251202

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122